1,1-Bis(3′-indolyl)-1-(p-substituted phenyl)methanes inhibit colon cancer cell and tumor growth through PPARγ-dependent and PPARγ-independent pathways

Molecular Cancer Therapeutics

Volumn 5, Issue 5, 2006, Pages 1362-1370

  Chintharlapalli, Sudhakar ^a   Papineni, Sabitha ^b   Safe, Stephen ^a,b,c  

^a TEXAS A AND M UNIVERSITY   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

^c TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,1 BIS(3' INDOLYL) 1 (PHENYL)METHANE DERIVATIVE; 2 CHLORO 5 NITROBENZANILIDE; ANTINEOPLASTIC AGENT; CAVEOLIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PROTEIN KINASE B; PROTEIN NAG 1; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CAVEOLIN 1; CELL PROLIFERATION; COLONIC NEOPLASMS; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; IMMUNOHISTOCHEMISTRY; INDOLES; MALE; MICE; MICE, NUDE; POLY(ADP-RIBOSE) POLYMERASES; PPAR GAMMA; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 33745095265     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0002     Document Type: Article

References (53)

1. Rosen ED, Spiegelman BM. PPAR-γ: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 2001;276:37731-4.
2. Willson RM, Lambert MH, Kliewer SA. Peroxisome proliferator-activated receptor γ and metabolic disease. Annu Rev Biochem 2001; 70:341-67.
3. Lee CH, Olson P, Evans RM. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 2003;144:2201-7.
4. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999;20:649-88.
5. Escher P, Wahli W. Peroxisome proliferator-activated receptors: insight into multiple cellular functions. Mutat Res 2000;448:121-38.
6. Fajas L, Debril MB, Auwerx J. Peroxisome proliferator-activated receptor-γ: from adipogenesis to carcinogenesis. J Mol Endocrinol 2001; 27:1-9.
7. Schopfer FJ, Lin Y, Baker PR, et al. Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor γ ligand. Proc Natl Acad Sci U S A 2005;102:2340-5.
8. Rieusset J, Touri F, Michalik L, et al. A new selective peroxisome proliferator-activated receptor γ antagonist with antiobesity and antidiabetic activity. Mol Endocrinol 2002;16:2628-44.
9. Berger JP, Petro AE, Macnaul KL, et al. Distinct properties and advantages of a novel peroxisome proliferator-activated protein γ selective modulator. Mol Endocrinol 2003;17:662-76.
10. Koyama H, Miller DJ, Boueres JK, et al. (2R)-2-Ethylchromane-2-carboxylic acids: discovery of novel PPARα/ dual agonists as antihyperglycemic and hypolipidemic agents. J Med Chem 2004;47:3255-63.
11. Acton JJ III, Black RM, Jones AB, et al. Benzoyl 2-methyl indoles as selective PPARγ modulators. Bioorg Med Chem Lett 2005;15:357-62.
12. Liu K, Black RM, Acton JJ III, et al. Selective PPARγ modulators with improved pharmacological profiles. Bioorg Med Chem Lett 2005;15: 2437-40.
13. Suh N, Wang Y, Honda T, et al. A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity. Cancer Res 1999;59:336-41.
14. Ikezoe T, Miller CW, Kawano S, et al. Mutational analysis of the peroxisome proliferator-activated receptor γ gene in human malignancies. Cancer Res 2001;61:5307-10.
15. Place AE, Suh N, Williams CR, et al. The novel synthetic triterpenoid, CDDO imidazolide, inhibits inflammatory response and tumor growth in vivo. Clin Cancer Res 2003;9:2798-806.
16. Qin C, Burghardt R, Smith R, et al. Peroxisome proliferator-activated receptor γ (PPAR) agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor α in MCF-7 breast cancer cells. Cancer Res 2003;63:958-64.
17. KiP1 in human pancreatic carcinoma cells. Cancer Res 2000;60:5558-64.
18. Chang TH, Szabo E. Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor γ in non-small cell lung cancer. Cancer Res 2000;60:1129-38.
19. Elstner E, Muller C, Koshizuka K, et al. Ligands for peroxisome proliferator-activated receptor γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci U S A 1998;95:8806-11.
20. Gupta RA, Sarraf P, Mueller E, et al. Peroxisome proliferator-activated receptor γ-mediated differentiation: a mutation in colon cancer cells reveals divergent and cell type-specific mechanisms. J Biol Chem 2003; 278:22669-77.
21. Brockman JA, Gupta RA, DuBois RN. Activation of PPARγ leads to inhibition of anchorage independent growth of human colorectal cancer cells. Gastroenterology 1998;115:1049-55.
22. Kato M, Kusumi T, Tsuchida S, et al. Induction of differentiation and peroxisome proliferator-activated receptor γ expression in colon cancer cell lines by troglitazone. J Cancer Res Clin Oncol 2004;130:73-9.
23. Gupta RA, Brockman JA, Sarraf P, Willson TM, DuBois RN. Target genes of peroxisome proliferator-activated receptor γ in colorectal cancer cells. J Biol Chem 2001;276:29681-7.
24. Kitamura S, Miyazaki Y, Shinomura Y, et al. Peroxisome proliferator-activated receptor γ induces growth arrest and differentiation markers of human colon cancer cells. Jpn J Cancer Res 1999;90:75-80.
25. Takahashi N, Okumura T, Motomura W, et al. Activation of PPARγ inhibits cell growth and induces apoptosis in human gastric cancer cells. FEBS Lett 1999;455:135-9.
26. 2-induced apoptosis does not require PPARγ in breast cancer cells. J Lipid Res 2002; 43:1818-28.
27. Baek SJ, Kim JS, Nixon JB, DiAugustine RP, Eling TE. Expression of NAG-1, a transforming growth factor-β superfamily member, by troglitazone requires the early growth response gene EGR-1. J Biol Chem 2004; 279:6883-92.
28. Inoue K, Kawahito Y, Tsubouchi Y, et al. Expression of peroxisome proliferator-activated receptor γ in renal cell carcinoma and growth inhibition by its agonists. Biochem Biophys Res Commun 2001;287: 727-32.
29. Baek SJ, Wilson LC, Hsi LC, Eling TE. Troglitazone, a peroxisome proliferator-activated receptor γ (PPARγ) ligand, selectively induces the early growth response-1 gene independently of PPARy. A novel mechanism for its anti-tumorigenic activity. J Biol Chem 2003;278:5845-53.
30. Niho N, Takahashi M, Kitamura T, at al. Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands. Cancer Res 2003;63: 6090-5.
31. Sarraf P, Mueller E, Jones D, et al. Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nat Med 1998;4: 1046-52.
32. Osawa E, Nakajima A, Wada K, et al. Peroxisome proliferator-activated receptor γ ligands suppress colon carcinogenesis induced by azoxymethane in mice. Gastroenterology 2003;124:361-7.
33. Niho N, Takahashi M, Shoji Y, et al. Dose-dependent suppression of hyperlipidemia and intestinal polyp formation in Min mice by pioglitazone, a PPARγ ligand. Cancer Sci 2003;94:960-4.
34. Sarkar FH, Li Y. Indole-3-carbinol and prostate cancer. J Nutr 2004; 134:3493-8S.
35. Shertzer HG, Senft AP. The micronutrient indole-3-carbinol: implications for disease and chemoprevention. Drug Metabol Drug Interact 2000; 17:159-88.
36. Qin C, Morrow D, Stewart J, et al. A new class of peroxisome proliferator-activated receptor γ (PPARγ) agonists that inhibit growth of breast cancer cells: 1,1-bis(3′-indolyl)-1-(P-substitutedphenyl)methanes. Mol Cancer Ther 2004;3:247-59.
37. Chintharlapalli S, Smith III R, Samudio I, Zhang W, Safe S. 1,1-Bis(3′-indolyl)-1-(p-substitutedphenyl)methanes induce peroxisome proliferator-activated receptor γ-mediated growth inhibition, transactivation and differentiation markers in colon cancer cells. Cancer Res 2004;64: 5994-6001.
38. Hong J, Samudio I, Liu S, Abdelrahim M, Safe S. Peroxisome proliferator-activated receptor γ-dependent activation of p21 in Panc-28 pancreatic cancer cells involves Sp1 and Sp4 proteins. Endocrinology 2004;145:5774-85.
39. Contractor R, Samudio I, Estrov Z, et al. A novel ring-substituted diindolylmethane 1,1-bis[3′-(5-methoxyindolyl)]-1-(p-t-butylphenyl)methane inhibits ERK activation and induces apoptosis in acute myeloid leukemia. Cancer Res 2005;65:2890-8.
40. Chintharlapalli S, Burghardt R, Papineni S, et al. Activation of Nur77 by selected 1,1-bis(3′-indolyl)]-1-(p-substituted phenyl)methanes induces apoptosis through nuclear pathways. J Biol Chem 2005;280:24903-14.
41. Chintharlapalli S, Papineni S, Baek SJ, Liu S, Safe S. 1,1-Bis(3′-indolyl)-1-(p-substitutedphenyl)methanes are peroxisome proliferator-activated receptor γ agonists but decrease HCT-116 colon cancer cell survival through receptor-independent activation of early growth response-1 and NAG-1. Mol Pharmacol 2005;68:1782-92.
42. Abdelrahim M, Newman K, Vanderlaag K, Samudio I, Safe S. 3,3′-Diindolylmethane (DIM) and derivatives induce apoptosis in pancreatic cancer cells through endoplasmic reticulum stress-dependent upregulation of DR5. Carcinogenesis 2006;27:717-28.
43. Chintharlapalli S, Papineni S, Konopleva M, et al. 2-Cyano-3,12-dioxoolean-1,9-dien-28-oic acid and related compounds inhibit growth of colon cancer cells through peroxisome proliferator-activated receptor γ-dependent and -independent pathways. Mol Pharmacol 2005;68:119-28.
44. Bender FC, Reymond MA, Bron C, Quest AF. Caveolin-1 levels are down-regulated in human colon tumors, and ectopic expression of caveolin-1 in colon carcinoma cell lines reduces cell tumorigenicity. Cancer Res 2000;60:5870-8.
45. Burgermeister E, Tencer L, Liscovitch M. Peroxisome proliferator-activated receptor-γ upregulates caveolin-1 and caveolin-2 expression in human carcinoma cells. Oncogene 2003; 22:3888-900.
46. Shack S, Wang XT, Kokkonen GC, et al. Caveolin-induced activation of the phosphatidylinositol 3-kinase/Akt pathway increases arsenite cytotoxicity. Mol Cell Biol 2003;23:2407-14.
47. Ono K, Iwanaga Y, Hirayama M, et al. Contribution of caveolin-1α and Akt to TNIF-α-induced cell death. Am J Physiol Lung Cell Mol Physiol 2004; 287:L201-9.
48. Baek SJ, Kim KS, Nixon JB, Wilson LC, Eling TE. Cyclooxygenase inhibitors regulate the expression of a TGF-β superfamily member that has proapoptotic and antitumorigenic activities. Mol Pharmacol 2001; 59: 901-8.
49. Baek SJ, Wilson LC, Eling TE. Resveratrol enhances the expression of nonsteroidal anti-inflammatory drug-activated gene (NAG-1) by increasing the expression of p53. Carcinogenesis 2002;23:425-34.
50. Kim JS, Baek SJ, Sali T, Eling TE. The conventional nonsteroidal antiinflammatory drug sulindac sulfide arrests ovarian cancer cell growth via the expression of NAG-1/MIC-1/GDF-15. Mol Cancer Ther 2005;4: 487-93.
51. Bottone FG, Jr., Baek SJ, Nixon JB, Eling TE. Diallyl disulfide (DADS) induces the antitumorigenic NSAID-activated gene (NAG-1) by a p53-dependent mechanism in human colorectal HCT 116 cells. J Nutr 2002; 132:773-8.
52. Li PX, Wong J, Ayed A, et al. Placental transforming growth factor-β is a downstream mediator of the growth arrest and apoptotic response of tumor cells to DNA damage and p53 overexpression. J Biol Chem 2000; 275:20127-35.
53. Liu T, Bauskin AR, Zaunders J, et al. Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer cells. Cancer Res 2003;63:5034-40.